Early-stage human trials of a second potential Russian Covid-19 vaccine, a peptide-based jab, were completed in Siberia this week.
Siberia’s Vector virology institute on TuesdayCommpleted early-stage human trials, known as Phase II, of a second potential Russian vaccine against Covid-19, the state consumer safety watchdog was cited by the Interfax news agency as saying.
Human trials of the second potential Covid-19 vaccine, a peptide-based jab, began on July 27 and involved a group of 100 volunteers, Interfax cited watchdog Rospotrebnadzor as saying.
“Today … the final group of 20 volunteers was released from the hospital,” said in a statement. “All 100 volunteers were vaccinated with two doses and have completed a 23-day monitoring period in hospital. The volunteers are feeling good.”
Results are due to be published on September 30, Interfax said.
Agencies
